These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 36779320)

  • 1. Validation of Linear Range HER2/Estrogen Receptor/Progesterone Receptor IHControls for Daily Quality Assurance.
    Sompuram SR; Vani K; Ryan L; Johnson C; Szabolcs M; Peruyero L; Balaton A; Pierrot S; Joseph L; Pilichowska M; Naber S; Goldsmith J; Green S; Bogen SA
    Am J Clin Pathol; 2023 Mar; 159(3):274-282. PubMed ID: 36779320
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Standardizing Immunohistochemistry: A New Reference Control for Detecting Staining Problems.
    Sompuram SR; Vani K; Tracey B; Kamstock DA; Bogen SA
    J Histochem Cytochem; 2015 Sep; 63(9):681-90. PubMed ID: 25940339
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitative Assessment of Immunohistochemistry Laboratory Performance by Measuring Analytic Response Curves and Limits of Detection.
    Sompuram SR; Vani K; Schaedle AK; Balasubramanian A; Bogen SA
    Arch Pathol Lab Med; 2018 Jul; 142(7):851-862. PubMed ID: 29595317
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Frequency and reliability of oestrogen receptor, progesterone receptor and HER2 in breast carcinoma determined by immunohistochemistry in Australasia: results of the RCPA Quality Assurance Program.
    Francis GD; Dimech M; Giles L; Hopkins A
    J Clin Pathol; 2007 Nov; 60(11):1277-83. PubMed ID: 17259294
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Importance of Epitope Density in Selecting a Sensitive Positive IHC Control.
    Vani K; Sompuram SR; Schaedle AK; Balasubramanian A; Pilichowska M; Naber S; Goldsmith JD; Chang KG; Noubary F; Bogen SA
    J Histochem Cytochem; 2017 Aug; 65(8):463-477. PubMed ID: 28665229
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Estrogen receptor (ER), progesterone receptor (PR), and HER2 expression pre- and post- neoadjuvant chemotherapy in primary breast carcinoma: a single institutional experience.
    Kinsella MD; Nassar A; Siddiqui MT; Cohen C
    Int J Clin Exp Pathol; 2012; 5(6):530-6. PubMed ID: 22949935
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An international study comparing conventional versus mRNA level testing (TargetPrint) for ER, PR, and HER2 status of breast cancer.
    Wesseling J; Tinterri C; Sapino A; Zanconati F; Lutke-Holzik M; Nguyen B; Deck KB; Querzoli P; Perin T; Giardina C; Seitz G; Guinebretière JM; Barone J; Dekker L; de Snoo F; Stork-Sloots L; Roepman P; Watanabe T; Cusumano P
    Virchows Arch; 2016 Sep; 469(3):297-304. PubMed ID: 27377889
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of immunohistochemistry and RT-qPCR for assessing ER, PR, HER2, and Ki67 and evaluating subtypes in patients with breast cancer.
    Chen L; Chen Y; Xie Z; Luo J; Wang Y; Zhou J; Huang L; Li H; Wang L; Liu P; Shu M; Zhang W; Ke Z
    Breast Cancer Res Treat; 2022 Aug; 194(3):517-529. PubMed ID: 35789315
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hormone receptor and HER2 assessment in breast carcinoma metastatic to bone: A comparison between FNA cell blocks and decalcified core needle biopsies.
    Zeng J; Piscuoglio S; Aggarwal G; Magda J; Friedlander MA; Murray M; Akram M; Reis-Filho JS; Weigelt B; Edelweiss M
    Cancer Cytopathol; 2020 Feb; 128(2):133-145. PubMed ID: 31883437
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 expression in breast cancer FNA cell blocks and paired histologic specimens: A large retrospective study.
    Vohra P; Buelow B; Chen YY; Serrano M; Vohra MS; Berry A; Ljung BM
    Cancer Cytopathol; 2016 Nov; 124(11):828-835. PubMed ID: 27315045
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Estrogen-Receptor, Progesterone-Receptor and HER2 Status Determination in Invasive Breast Cancer. Concordance between Immuno-Histochemistry and MapQuant™ Microarray Based Assay.
    Mouttet D; Laé M; Caly M; Gentien D; Carpentier S; Peyro-Saint-Paul H; Vincent-Salomon A; Rouzier R; Sigal-Zafrani B; Sastre-Garau X; Reyal F
    PLoS One; 2016; 11(2):e0146474. PubMed ID: 26829108
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analytical and clinical performance of progesterone receptor antibodies in breast cancer.
    Calhoun BC; Mosteller B; Warren D; Smith M; Jordi Rowe J; Lanigan CP; Mrazeck KC; Walker E; Newell AH; Jones R
    Ann Diagn Pathol; 2018 Aug; 35():21-26. PubMed ID: 29758480
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparing breast biomarker status between routine immunohistochemistry and FISH studies and Oncotype DX testing, a study of 610 cases.
    Neely C; You S; Mendoza PM; Aneja R; Sahin AA; Li X
    Breast J; 2018 Nov; 24(6):889-893. PubMed ID: 30230095
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of Web-based training for quality improvement between a field immunohistochemistry laboratory in Nigeria and its United States-based partner institution.
    Oluwasola AO; Malaka D; Khramtsov AI; Ikpatt OF; Odetunde A; Adeyanju OO; Sveen WE; Falusi AG; Huo D; Olopade OI
    Ann Diagn Pathol; 2013 Dec; 17(6):526-30. PubMed ID: 24095629
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunohistochemistry subtypes (ER/PR/HER) of breast cancer: where do we stand in the West of Saudi Arabia?
    Khabaz MN
    Asian Pac J Cancer Prev; 2014; 15(19):8395-400. PubMed ID: 25339035
    [TBL] [Abstract][Full Text] [Related]  

  • 16. External quality assessment (EQA) program for the immunohistochemical detection of ER, PR and Ki-67 in breast cancer: results of an interlaboratory reproducibility ring study in China.
    Pu T; Shui R; Shi J; Liang Z; Yang W; Bu H; Li Q; Zhang Z;
    BMC Cancer; 2019 Oct; 19(1):978. PubMed ID: 31640622
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Variability of predictive markers (hormone receptors, Her2, Ki67) and intrinsic subtypes of breast cancer in four consecutive years 2015-2018.
    Stevanovic L; Choschzick M; Moskovszky L; Varga Z
    J Cancer Res Clin Oncol; 2019 Dec; 145(12):2983-2994. PubMed ID: 31628534
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunohistochemical detection of estrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 in formalin-fixed breast carcinoma cell block preparations: correlation of results to corresponding tissue block (needle core and excision) samples.
    Kinsella MD; Birdsong GG; Siddiqui MT; Cohen C; Hanley KZ
    Diagn Cytopathol; 2013 Mar; 41(3):192-8. PubMed ID: 22611048
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Study on breast carcinoma Her2/neu and hormonal receptors status assessed by automated images analysis systems: ACIS III (Dako) and ScanScope (Aperio).
    Słodkowska J; Filas V; Buszkiewicz E; Trzeciak P; Wojciechowski M; Koktysz R; Staniszewski W; Breborowicz J; Rojo MG
    Folia Histochem Cytobiol; 2010 Jan; 48(1):19-25. PubMed ID: 20529811
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metastatic breast carcinoma in pleural fluid: Correlation of receptor and HER2 status with the primary carcinoma-a pilot study.
    Francis IM; Alath P; George SS; Jaragh M; Al Jassar A; Kapila K
    Diagn Cytopathol; 2016 Dec; 44(12):980-986. PubMed ID: 27666130
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.